<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085527</url>
  </required_header>
  <id_info>
    <org_study_id>12965A</org_study_id>
    <secondary_id>UCCRC-12965</secondary_id>
    <secondary_id>LUMC-106995</secondary_id>
    <secondary_id>NCI-6347</secondary_id>
    <nct_id>NCT00085527</nct_id>
  </id_info>
  <brief_title>FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer</brief_title>
  <official_title>A Phase II Study Of Depsipeptide In Patients With Relapsed Or Refractory Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with&#xD;
      relapsed or refractory advanced ovarian epithelial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate (complete and partial) in patients with relapsed or&#xD;
           refractory advanced ovarian epithelial carcinoma treated with FR901228 (depsipeptide).&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate clinical response with platinum sensitivity in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Correlate clinical response with P-glycoprotein expression or p53 status in patients&#xD;
           treated with this drug.&#xD;
&#xD;
      OUTLINE: This is multicenter study. Patients are stratified according to response to prior&#xD;
      platinum administration (platinum resistant vs platinum sensitive).&#xD;
&#xD;
      Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-37 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of depsipeptide in ovarian cancer</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>depsipeptide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depsipeptide administered on Days 1, 8, and15 of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>depsipeptide</intervention_name>
    <arm_group_label>depsipeptide</arm_group_label>
    <other_name>Romidepsin, Istodax®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed ovarian epithelial carcinoma&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
          -  Relapsed after OR refractory to 1, and only 1, prior platinum- or taxane-based regimen&#xD;
&#xD;
               -  Refractory disease defined as disease progression during platinum- or&#xD;
                  taxane-based therapy&#xD;
&#xD;
               -  Relapsed disease defined as platinum or taxane resistant or sensitive&#xD;
&#xD;
                    -  Platinum or taxane resistance defined as relapse within 6 months after prior&#xD;
                       platinum or taxane therapy&#xD;
&#xD;
                    -  Platinum or taxane sensitivity defined as relapse &gt; 6 months from the last&#xD;
                       platinum or taxane treatment&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Measurable disease defined as at least 1 unidimensionally measurable lesion ≥ 20&#xD;
                  mm by conventional techniques OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Evaluable disease determined by elevation in CA 125 (≥ 2 times upper limit of&#xD;
                  normal [ULN]), ascites, or pleural effusion&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  SWOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 24 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  QTc &lt; 500 msec&#xD;
&#xD;
          -  LVEF &gt; 40% by MUGA&#xD;
&#xD;
          -  No significant cardiac disease&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable or poorly controlled angina pectoris&#xD;
&#xD;
          -  No uncontrolled dysrhythmias&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No prior serious ventricular arrhythmia (ventricular tachycardia or ventricular&#xD;
             fibrillation ≥ 3 beats in a row)&#xD;
&#xD;
          -  No left ventricular hypertrophy by EKG&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Potassium ≥ 4.0 mmol/L&#xD;
&#xD;
          -  Magnesium ≥ 2.0 mg/dL&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to FR901228 (depsipeptide)&#xD;
&#xD;
          -  No concurrent uncontrolled illness&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent biologic agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior FR901228 (depsipeptide)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Prior surgical resection allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent drugs known to have HDI activity (e.g., sodium valproate)&#xD;
&#xD;
          -  No concurrent agents that cause QTc prolongation&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent hydrochlorothiazide&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gini Fleming, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

